ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: 84% Of Micromet Shares Have Been Tendered

DOW JONES NEWSWIRES Amgen Inc. (AMGN) said nearly 84% of the shares of biotechnology company Micromet Inc. (MITI) have been tendered to its $1.16 billion takeover offer, meeting all the conditions for the acquisition to close. As of the offering's expiration Thursday, about 80 million Micromet shares had been tendered and not withdrawn. An added 3.15 million shares have been tendered by guaranteed delivery. A subsequent offering period is scheduled to expire at 12:00 a.m. EST, at the end of March 6. Amgen launched its bid to acquire Micromet in January with an aim to strengthen Amgen's cancer-drug research pipeline. A Delaware judge declined to block Amgen's purchase of Micromet, the Associated Press reported Thursday. A group of Micromet shareholders had argued that Micromet didn't try hard enough to get a better offer, and sought a preliminary injunction. The judge found that the shareholders didn't show a reasonable likelihood that they would successfully prove their claims, the AP reported. Amgen shares closed at $67.59 Thursday and were inactive premarket. The stock is up 32% in the past 12 months. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/27/201617:00:00Amgen Profit Rises 13%, 2016 Outlook Raised
07/27/201616:31:36Current Report Filing (8-k)
07/27/201616:01:00Amgen Reports Second Quarter 2016 Financial Results
07/22/201616:30:00Amgen Announces Webcast Of 2016 Second Quarter Financial Results
07/22/201616:00:00Amgen Announces 2016 Third Quarter Dividend
07/22/201601:00:00Amgen And UCB Submit Biologics License Application For Romosozumab...
07/21/201612:50:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21/201612:37:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21/201609:00:00Amgen And Allergan Announce Top-Line Results From Phase 3 Study...
07/20/201620:29:00Amgen Announces Settlement Of Securities Litigation
07/20/201607:40:00Technical Coverage on Biotechnology Equities -- Galena Biopharma...
07/13/201621:00:00Amgen And Daiichi Sankyo Announce Agreement To Commercialize...
07/12/201619:20:00Amgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12/201607:30:00Amgen To Discuss Data Supporting Biologics License Application...
07/11/201609:00:00FDA Approves First And Only Single Monthly Injection For A PCSK9...
07/06/201617:50:00Western Digital Names New CFO, Boosts Guidance
07/04/201601:00:00European Commission Approves Extended Indication For Amgen's...
06/22/201618:00:00Amgen Sponsors QB3@953 Incubator For Life Science Startups
06/20/201608:25:00Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa...
06/17/201616:00:00Amgen Appoints Esteban Santos Executive Vice President, Operations

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad